Generalized Myasthenia Gravis Clinical Trial
Official title:
A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)
The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previously treated with batoclimab will be re-randomized to stay on batoclimab (340 mg SC QW or 340 mg SC every two weeks) or receive placebo treatment. The secondary endpoint of maintenance of efficacy will be assessed by change in the MG- ADL score in AChRAb+ participants. Participants demonstrating a response to batoclimab during either Period 1 or 2 may enter the long-term extension (Period 3). Participants who complete Period 3 are eligible to participate in Period 4 (Optional Long-Term extension) according to their treatment assignment in Period 3.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05514873 -
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
|
Phase 3 | |
| Completed |
NCT04124965 -
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT04833894 -
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04963270 -
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Active, not recruiting |
NCT02950155 -
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
|
Phase 3 | |
| Completed |
NCT03315130 -
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
|
Phase 2 | |
| Recruiting |
NCT05556096 -
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
|
Phase 3 | |
| Not yet recruiting |
NCT06392386 -
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
|
Phase 3 | |
| Not yet recruiting |
NCT06149559 -
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06193889 -
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
| Completed |
NCT03920293 -
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
|
Phase 3 | |
| Completed |
NCT03770403 -
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
|
Phase 3 | |
| Not yet recruiting |
NCT06447597 -
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
|
Phase 2/Phase 3 | |
| Completed |
NCT03971422 -
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT05644561 -
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
|
Phase 3 | |
| Not yet recruiting |
NCT06456580 -
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)
|
Phase 3 | |
| Not yet recruiting |
NCT06463587 -
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
|
Phase 3 | |
| Recruiting |
NCT06055959 -
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
| Completed |
NCT00515450 -
Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT06064695 -
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis
|
N/A |